141 related articles for article (PubMed ID: 31388783)
1. Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib.
Pathade AD; Kommineni N; Bulbake U; Thummar MM; Samanthula G; Khan W
AAPS PharmSciTech; 2019 Aug; 20(7):276. PubMed ID: 31388783
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS.
Ottria R; Ravelli A; Miceli M; Casati S; Orioli M; Ciuffreda P
Molecules; 2019 Mar; 24(5):. PubMed ID: 30862103
[TBL] [Abstract][Full Text] [Related]
3. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
Moore KN; Birrer MJ
Oncologist; 2018 Jun; 23(6):697-703. PubMed ID: 29593098
[TBL] [Abstract][Full Text] [Related]
4. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
[TBL] [Abstract][Full Text] [Related]
5. Olaparib: A tale of two dosage forms.
Christ TN
Semin Oncol; 2019 Feb; 46(1):100-101. PubMed ID: 30583807
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?
Perego G; Nozza R; Oggionni E; Cabiddu M; Scolari C; Omati E; Castelli EA; Petrelli F
J Oncol Pharm Pract; 2020 Jun; 26(4):967-971. PubMed ID: 32041467
[TBL] [Abstract][Full Text] [Related]
7. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
8. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Zhou D; Li J; Bui K; Learoyd M; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H
Clin Pharmacokinet; 2019 May; 58(5):615-625. PubMed ID: 30357650
[TBL] [Abstract][Full Text] [Related]
9. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
[TBL] [Abstract][Full Text] [Related]
10. Olaparib for the treatment of ovarian cancer.
Bornstein E; Jimeno A
Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
[TBL] [Abstract][Full Text] [Related]
11. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J; Moreno V; Gupta A; Kaye SB; Dean E; Middleton MR; Friedlander M; Gourley C; Plummer R; Rustin G; Sessa C; Leunen K; Ledermann J; Swaisland H; Fielding A; Bannister W; Nicum S; Molife LR
Target Oncol; 2016 Jun; 11(3):401-15. PubMed ID: 27169564
[TBL] [Abstract][Full Text] [Related]
12. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Munroe M; Kolesar J
Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
[TBL] [Abstract][Full Text] [Related]
13. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
14. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
15. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Rolfo C; Swaisland H; Leunen K; Rutten A; Soetekouw P; Slater S; Verheul HM; Fielding A; So K; Bannister W; Dean E
Adv Ther; 2015 Jun; 32(6):510-22. PubMed ID: 26048134
[TBL] [Abstract][Full Text] [Related]
16. PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells.
Schacke M; Kumar J; Colwell N; Hermanson K; Folle GA; Nechaev S; Dhasarathy A; Lafon-Hughes L
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691122
[TBL] [Abstract][Full Text] [Related]
17. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
18. Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
Wang W; Xiong Y; Hu X; Lu F; Qin T; Zhang L; Guo E; Yang B; Fu Y; Hu D; Fan J; Qin X; Liu C; Xiao R; Chen G; Li Z; Sun C
Acta Biomater; 2023 Feb; 157():428-441. PubMed ID: 36549633
[TBL] [Abstract][Full Text] [Related]
19. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
20. Nanocrystallization Improves the Solubilization and Cytotoxic Effect of a Poly (ADP-Ribose)-Polymerase-I Inhibitor.
Alali AS; Kalam MA; Ahmed MM; Aboudzadeh MA; Alhudaithi SS; Anwer MK; Fatima F; Iqbal M
Polymers (Basel); 2022 Nov; 14(22):. PubMed ID: 36432955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]